Network Bio launched with $50 million in financing and a collaboration valued at $30 million with NVIDIA to develop a cell-free RNA (cfRNA) foundation model. The startup said it will use large-scale, multimodal datasets assembled through partnerships with academic biobanks, including longitudinal clinical outcomes, to train models for diagnostics, biomarker discovery, and drug development. Network Bio plans to combine the tissue-and-blood-derived cfRNA data with NVIDIA’s Parabricks sequence analysis software and open-source BioNeMo Recipes to streamline model building from biobank access to model-ready inputs. The partners also plan to create a population-scale cfRNA foundation model intended to support supervised downstream models across oncology and non-oncology indications. A separate reporting note previously described Network Bio’s launch narrative around building disease-specific and foundation models and early commercial validation through a co-development and licensing agreement.